

Thomas M Jenkins

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7344713/publications.pdf>

Version: 2024-02-01

38
papers

813
citations

623734

14
h-index

526287

27
g-index

42
all docs

42
docs citations

42
times ranked

1346
citing authors

#	ARTICLE	IF	CITATIONS
1	Muscle MRI in motor neuron diseases: a systematic review. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2022, 23, 161-175.	1.7	12
2	Assessment of the Precision in Measuring Glutathione at 3T With a MEGA-PRESS Sequence in Primary Motor Cortex and Occipital Cortex. <i>Journal of Magnetic Resonance Imaging</i> , 2022, 55, 435-442.	3.4	2
3	VoxelHop: Successive Subspace Learning for ALS Disease Classification Using Structural MRI. <i>IEEE Journal of Biomedical and Health Informatics</i> , 2022, 26, 1128-1139.	6.3	10
4	Reinnervation as measured by the motor unit size index is associated with preservation of muscle strength in amyotrophic lateral sclerosis, but not all muscles reinnervate. <i>Muscle and Nerve</i> , 2022, 65, 203-210.	2.2	6
5	Multicentre appraisal of amyotrophic lateral sclerosis biofluid biomarkers shows primacy of blood neurofilament light chain. <i>Brain Communications</i> , 2022, 4, fcac029.	3.3	29
6	COVID-19 vaccination hesitancy among people with chronic neurological disorders: A position paper. <i>European Journal of Neurology</i> , 2022, 29, 2163-2172.	3.3	13
7	Simultaneous ALS and SCA2 associated with an intermediate-length <i>ATXN2</i> CAG-repeat expansion. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2021, 22, 579-582.	1.7	13
8	Primary prevention of COVID-19: Advocacy for vaccination from a neurological perspective. <i>European Journal of Neurology</i> , 2021, 28, 3226-3229.	3.3	13
9	A plea for equitable global access to COVID-19 diagnostics, vaccination and therapy: The NeuroCOVID-19 Task Force of the European Academy of Neurology. <i>European Journal of Neurology</i> , 2021, 28, 3849-3855.	3.3	14
10	Value of systematic genetic screening of patients with amyotrophic lateral sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 510-518.	1.9	69
11	Longitudinal multi-modal muscle-based biomarker assessment in motor neuron disease. <i>Journal of Neurology</i> , 2020, 267, 244-256.	3.6	15
12	Ursodeoxycholic acid as a novel disease-modifying treatment for Parkinson's disease: protocol for a two-centre, randomised, double-blind, placebo-controlled trial, The 'UP' study. <i>BMJ Open</i> , 2020, 10, e038911.	1.9	18
13	Neurological letter from Bangladesh. <i>Practical Neurology</i> , 2020, 20, 435.2-445.	1.1	0
14	Magnetic resonance spectroscopy reveals mitochondrial dysfunction in amyotrophic lateral sclerosis. <i>Brain</i> , 2020, 143, 3603-3618.	7.6	24
15	Cognitive deficits in vasculitis of the nervous system: a cross-sectional study. <i>Postgraduate Medicine</i> , 2019, 131, 546-549.	2.0	2
16	Nocebo in chronic inflammatory demyelinating polyneuropathy; a systematic review and meta-analysis of placebo-controlled clinical trials. <i>Journal of the Neurological Sciences</i> , 2018, 388, 79-83.	0.6	16
17	Imaging muscle as a potential biomarker of denervation in motor neuron disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, 248-255.	1.9	41
18	Translational approaches to restoring mitochondrial function in Parkinson's disease. <i>FEBS Letters</i> , 2018, 592, 776-792.	2.8	10

#	ARTICLE	IF	CITATIONS
19	Optic neuritis: the eye as a window to the brain. <i>Current Opinion in Neurology</i> , 2017, 30, 61-66.	3.6	47
20	PO215â€¦Outcomes of neurology admissions to critical care. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017, 88, A68.3-A68.	1.9	0
21	The role of cranial and thoracic electromyography within diagnostic criteria for amyotrophic lateral sclerosis. <i>Muscle and Nerve</i> , 2016, 54, 378-385.	2.2	6
22	Longitudinal evidence for anterograde trans-synaptic degeneration after optic neuritis. <i>Brain</i> , 2016, 139, 816-828.	7.6	67
23	A wolf in sheep's clothing. <i>Practical Neurology</i> , 2016, 16, 153-156.	1.1	0
24	The evidence for symptomatic treatments in amyotrophic lateral sclerosis. <i>Current Opinion in Neurology</i> , 2014, 27, 524-531.	3.6	41
25	Optical coherence tomography should be part of the routine monitoring of patients with multiple sclerosis: No. <i>Multiple Sclerosis Journal</i> , 2014, 20, 1299-1301.	3.0	6
26	Visual Acuity, Eye Movements and Visual Fields. , 2014, , 75-88.		5
27	Clinical and Molecular Aspects of Motor Neuron Disease. <i>Colloquium Series on Genomic and Molecular Medicine</i> , 2013, 2, 1-60.	0.2	18
28	A prospective pilot study measuring muscle volumetric change in amyotrophic lateral sclerosis. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2013, 14, 414-423.	1.7	14
29	A longitudinal functional MRI study of non-arteritic anterior ischaemic optic neuropathy patients. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2011, 82, 905-913.	1.9	8
30	Dissecting structureâ€“function interactions in acute optic neuritis to investigate neuroplasticity. <i>Human Brain Mapping</i> , 2010, 31, 276-286.	3.6	34
31	Neuroplasticity predicts outcome of optic neuritis independent of tissue damage. <i>Annals of Neurology</i> , 2010, 67, 99-113.	5.3	75
32	New developments in the treatment of optic neuritis. <i>Eye and Brain</i> , 2010, 2, 83.	2.5	6
33	Combining tractography and cortical measures to test system-specific hypotheses in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2010, 16, 555-565.	3.0	33
34	Contiguousâ€“slice zonally oblique multislice (COâ€“ZOOM) diffusion tensor imaging: Examples of in vivo spinal cord and optic nerve applications. <i>Journal of Magnetic Resonance Imaging</i> , 2009, 29, 454-460.	3.4	48
35	Assessing structure and function of the afferent visual pathway in multiple sclerosis and associated optic neuritis. <i>Journal of Neurology</i> , 2009, 256, 305-319.	3.6	94
36	Diagnosing and managing multiple sclerosis. <i>Practitioner</i> , 2009, 253, 25-30, 2-3.	0.3	2

#	ARTICLE	IF	CITATIONS
37	GPs have pivotal role in managing MS. Practitioner, 2007, 251, 37-40, 42-3, 46 passim.	0.3	0
38	A Dysphasic Diabetic with Confusion and Fever. Practical Neurology, 2005, 5, 230-235.	1.1	0